Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

175
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
175
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

266
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
266
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

393
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
393
Pneumonia IV: Management01:28

Pneumonia IV: Management

691
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
691
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

182
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
182

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Interplay of Noncovalent Interactions in Phase Separation Mediated by Tyrosine-Rich and Arginine-Rich Polypeptides.

Journal of the American Chemical Society·2026
Same author

Potent and biased agonists of class B1 GPCRs from a heterochiral design strategy.

Nature chemistry·2026
Same author

Bifunctional Catalysis of a Crossed Aldol Condensation by Diamines: Impact of Tether Composition and Length.

The Journal of organic chemistry·2026
Same author

Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread.

Journal of virology·2026
Same author

Altered Intracellular Trafficking as a Mechanism for Prolonged Duration of G Protein-Coupled Receptor Activation.

Journal of the American Chemical Society·2026
Same author

Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins.

Cell host & microbe·2026

相关实验视频

Updated: Dec 30, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.4K

双HPIV3/RSV融合抑制剂的结构导向改进

Victor K Outlaw1, Jennifer T Lemke1, Yun Zhu2,3

  • 1Department of Chemistry , University of Wisconsin , Madison , Wisconsin 53706 , United States.

Journal of the American Chemical Society
|January 18, 2020
PubMed
概括

新的衍生物对人类类型3型流感病毒 (HPIV3) 和呼吸道同胞病毒 (RSV) 感染的疗效有所提高. 这些双重抑制剂向融合糖蛋白,为治疗这些常见的呼吸系统疾病提供了有前途的策略.

更多相关视频

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.9K
Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

5.9K

相关实验视频

Last Updated: Dec 30, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.4K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

16.9K
Assembly and Purification of Prototype Foamy Virus Intasomes
10:20

Assembly and Purification of Prototype Foamy Virus Intasomes

Published on: March 19, 2018

5.9K

科学领域:

  • 病毒学
  • 结构生物学
  • 药物发现

背景情况:

  • 人类类流感病毒3 (HPIV3) 和呼吸道同胞病毒 (RSV) 是严重呼吸道感染的主要原因.
  • 目前对HPIV3和RSV的治疗方法有限,没有现有的疫苗或抗病毒疗法.

研究的目的:

  • 设计和开发针对HPIV3和RSV融合糖蛋白的新型抑制剂.
  • 提高之前确定的双重抑制剂的疗效和稳定性.

主要方法:

  • 基于HPIV3融合糖蛋白的抑制剂的结构导向设计.
  • 在VIQKI序列中引入氨酸替代.
  • 抑制剂融合蛋白域复合物的晶体分析.
  • 对HPIV3和RSV感染的疗效进行抗病毒检测.

主要成果:

  • 具有氨酸替代物的VIQKI衍生物对HPIV3和RSV具有增强的抗病毒活性.
  • I456F和I454F/ I456F替代导致与病毒融合蛋白域的相互作用更加稳定.
  • 结晶结构显示出特定的疏水相互作用,有助于增强结合和抑制.

结论:

  • 对VIQKI的结构导向修改显著提高了其对HPIV3和RSV的双重抑制潜力.
  • 开发的氨酸替代抑制剂代表了对抗HPIV3和RSV感染的有希望的治疗策略.